Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Subject collections
    • Interviews
    • Alerts
  • About us
    • About DMM
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Workshops and Meetings
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • Outstanding paper prize
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Alerts
  • Contact
    • Contact DMM
    • Advertising
    • Feedback
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

User menu

  • Log in

Search

  • Advanced search
Disease Models & Mechanisms
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

supporting biologistsinspiring biology

Disease Models & Mechanisms

Advanced search

RSS   Twitter   Facebook   YouTube

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Subject collections
    • Interviews
    • Alerts
  • About us
    • About DMM
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Workshops and Meetings
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • Outstanding paper prize
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Alerts
  • Contact
    • Contact DMM
    • Advertising
    • Feedback
Journal Club
From white to brown fat through the PGC-1α-dependent myokine irisin: implications for diabetes and obesity
Jorge Iván Castillo-Quan
Disease Models & Mechanisms 2012 5: 293-295; doi: 10.1242/dmm.009894
Jorge Iván Castillo-Quan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & tables
  • Info & metrics
  • PDF
Loading

Summary and comment on a recent Nature paper entitled ‘A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis’ (Boström et al., 2012).

The benefits of good diet and exercise have been extensively documented, and are the cornerstones for non-pharmacological treatment of cardiovascular and metabolic diseases (Dunstan, 2011). However, the molecular mechanisms by which exercise exerts its positive effects remain largely unexplained. An ongoing challenge in the field is to identify these mechanisms, enabling the development of exercise-mimetic drugs (Narkar et al., 2008).

A well-described effect of exercise is ‘browning’ of white adipose tissue (WAT) – that is, exercise increases the relative amount of brown adipose tissue (BAT). In contrast to the primarily fat-storing function of WAT, BAT has non-shivering thermogenic properties owing to expression of uncoupling protein-1 (UCP1) and increased mitochondrial content (Handschin and Spiegelman, 2008; Lidell and Enerbäck, 2010; Ravussin and Galgani, 2011). In addition, higher BAT levels are associated with resistance to metabolic diseases. Induction of a browning programme in rodents reduces body weight and improves glucose homeostasis (Zhou et al., 2003). Although it was previously thought that, in humans, BAT regresses with age to an almost non-existent brown depot in adults, recent evidence has proven otherwise (Virtanen et al., 2009; van Marken Lichtenbelt et al., 2009; Zingaretti et al., 2009). Importantly, however, van Marken Lichtenbelt et al. showed that the amount of BAT is significantly lower in overweight or obese subjects, and that there is a negative relationship between BAT and both body mass index and percentage of body fat (van Marken Lichtenbelt et al., 2009). Therefore, it is clear that BAT is both present and functional in adult humans, and that lower amounts of BAT are associated with obesity. An exciting new study from the Spiegelman laboratory has now uncovered a molecular mechanism by which exercise-induced browning can occur, involving a newly identified PGC-1α-induced myokine (Boström et al., 2012) (Fig. 1).

PGC-1α is a transcriptional coactivator that regulates genes in response to nutritional and physiological cues (Finck and Kelly, 2006). Exercise (particularly chronic) is accompanied by increased muscle expression of PGC-1α, whereas type 2 diabetes or a sedentary lifestyle are associated with reduced expression [see Handschin and Spiegelman, and references therein (Handschin and Spiegelman, 2008)]. Increasing the muscle expression of PGC-1α in mice protects against weight gain, inflammation, oxidative stress, muscle wasting and bone loss. Moreover, increasing PGC-1α expression improves metabolic parameters such as insulin sensitivity and insulin signalling (Wenz et al., 2009). However, it is still largely unknown how a single transcriptional coactivator can mediate such broad systemic effects and, particularly, how muscle-specific expression can influence whole-body metabolism. Boström et al. shed light on this issue by identifying a muscle-derived secreted factor that mediates systemic effects (Boström et al., 2012).

First, Boström and colleagues identified that muscle-specific overexpression of PGC-1α induced a brown-like adipose tissue gene programme. Mice overexpressing PGC-1α showed markedly increased levels of BAT-associated transcripts, including Ucp1 and Cidea, in the subcutaneous inguinal fat layer, correlating with increased UCP1 expression in WAT (Boström et al., 2012). A similar genetic profile was induced by 3 weeks of wheel running, indicating that muscle-specific PGC-1α expression and exercise both triggered a ‘browning’ programme in WAT (Boström et al., 2012).

To determine the mechanism behind this effect, Boström et al. treated subcutaneous adipocytes with either control medium or medium from cells ectopically expressing PGC-1α (Boström et al., 2012). The latter induced a brown-like genetic programme, suggesting that a secreted molecule from the muscle cells was responsible for inducing browning of WAT.

To identify the secreted molecule, the authors combined Affymetrix gene expression arrays and an algorithm to predict secreted peptides. This led to the identification of five candidates: IL-15, FNDC5, VEGF-β, LRG1 and TIMP4. Importantly, these factors were also upregulated in the muscles of mice and humans after endurance exercise. Additional experiments implicated FNDC5 as the most likely candidate mediating the browning effect; its action was stronger than the known inducer, BMP7. In vitro, FNDC5-treated undifferentiated white adipocytes became UCP1-positive, and showed increased mitochondrial density and mitochondrial gene expression. FNDC5 treatment also augmented oxygen consumption and energy expenditure, with the majority of respiration being uncoupled.

Next, Boström et al. addressed how muscle FNDC5, a type I transmembrane protein, gets into the adipose tissue, and determined that FNDC5 is C-terminally cleaved and secreted into the media (Boström et al., 2012). They named this previously undescribed portion of FNDC5 irisin, after the Greek messenger goddess Iris. To determine whether irisin was involved in mediating the PGC-1α-induced browning of WAT, they treated medium from PGC-1α-expressing muscle cells with anti-FNDC5 before supplementing it to adipocytes. This treatment completely blocked the induction of the browning programme.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Exercise-induced adipose tissue browning through PGC-1α and irisin. Exercise increases the expression levels of PGC-1α in the muscle. This, in turn, upregulates the expression of FNDC5, a type I membrane protein, which is C-terminally cleaved and secreted as irisin into the circulation. Binding of irisin to an unknown receptor on the surface of adipocytes in WAT changes their genetic profile. In particular, irisin induces the expression of PPAR-α, which is thought to be an intermediate downstream effector that increases the expression of UCP1 (highly expressed in BAT and a marker of browning). The browning of WAT is associated with augmented mitochondrial density and oxygen consumption. Browning is accompanied by an increase in the energy expenditure profile, leading to favourable effects on metabolism.

Boström and colleagues found irisin in the plasma of wild-type mice, and showed that muscle-specific knockout of PGC-1α decreased irisin levels by 72%. Notably, they also identified a band of similar electrophoretic mobility in the plasma of healthy human subjects. After 3 weeks of free wheel running, plasma irisin levels had increased by 65% in mice and, correspondingly, plasma irisin levels were found to double in healthy humans after 10 weeks of endurance exercise.

The authors also investigated at the molecular level how irisin induces browning; in particular, they analysed the upregulation of UCP1 expression. Gene arrays indicated that one possible mechanism might be increased expression of PPAR-α. PPAR-α is a member of the PPAR family of ligand-activated receptors, which have become relevant as therapeutic targets owing to their roles in lipid and glucose metabolism and vascular biology (Hiukka et al., 2010). FNDC5 induced a threefold increase in Ppara mRNA levels in white adipocytes differentiated from stromal vascular cells. Moreover, pharmacological inhibition with a PPAR-α-selective antagonist limited the induction of the browning programme by FNDC5, indicating that the increased expression of UCP1 and browning of WAT by FNDC5 are at least partially mediated via PPAR-α.

Boström et al. then evaluated whether FNDC5 was functional in vivo, and whether it could improve disease in a mouse model of diet-induced obesity and insulin resistance (Boström et al., 2012). They first established in control mice that delivery of FNDC5 by adenoviral vectors increased Fndc5 mRNA by 15-fold and plasma levels of irisin by three- to fourfold. At 10 days post-injection, a 13-fold increase in Ucp1 mRNA levels was detected, accompanied by significantly higher expression of Cidea. Next, they showed that delivery of FNDC5-expressing adenovirus to high-fat-fed C57BL/6 mice showed similar browning patterns. Importantly, this modest increase of irisin (threefold) was accompanied by increased oxygen consumption, a slight but significant reduction in body weight, improved glucose tolerance and reduced fasting insulin levels.

Finally, Boström and colleagues tested whether irisin is necessary for the exercise-induced gene-browning programme by injecting anti-FNDC5 antibody into mice before swimming training and showed that this caused a complete blockade of the response, as measured by Ucp1 and Cidea mRNA levels. Hence, in addition to inducing a browning genotype and phenotype that improves the metabolic parameters in a disease model, irisin is also required for the exercise-induced browning of WAT.

In summary, Boström et al. showed that increased levels of PGC-1α in muscle cells induced the expression of the type I membrane protein FNDC5, which is cleaved and secreted into the circulation (Boström et al., 2012). The secreted portion of FNDC5, a newly identified myokine known as irisin, binds to undetermined receptors on the surface of WAT. By an incompletely understood mechanism, irisin induced the expression of Ucp1 and other BAT-associated genes, partly via increased PPAR-α expression. Thus, irisin functions as a muscle-derived energy-expenditure signal that directly communicates with adipose tissue and induces browning. This effect improved the tissue metabolic profile and increased whole-body energy expenditure, making irisin a potential new target for the treatment of metabolic diseases (Fig. 1).

An important next step will be to identify the specific molecular pathways that underlie browning. Boström and colleagues identified PPAR-α as a key factor for the expression of UCP1, but there are probably other proteins involved. For example, another member of the PPAR family has been implicated as a candidate for browning. Recently, Ohno et al. showed that PPAR-γ ligands, coupled with PRDM16 (a determinant for the development of BAT), could switch subcutaneous white adipose cells to a BAT programme (Ohno et al., 2012). Another important observation was recently made by Ortega-Molina et al., who determined that inhibition of PI3K signalling by overexpression of its natural repressor, PTEN, can cause browning of WAT (Ortega-Molina et al., 2012). It will be thought provoking to address whether and how different browning programmes can work together. Moreover, other molecules such as AMPK and PPAR-δ have been put forward as exercise mimetics (Narkar et al., 2008), so it will be interesting to explore these in the context of irisin.

The implications of these findings for metabolic diseases are broad and exciting, particularly because the authors showed that irisin is present in humans and increases in response to endurance exercise. Although browning of WAT has not been described in humans, the existence of functional BAT depots in adults suggests that the conversion observed in rodents might be conserved. Reflecting the animal studies presented by Boström et al., could FNDC5 (or irisin) be delivered in humans in a similar way to increase irisin plasma levels? However, it will be crucial to investigate other potential effects of circulating irisin, beyond those described by Boström et al., on other metabolic tissues such as hepatocytes, and smooth or cardiac muscle.

In summary, this study will undoubtedly stimulate more PGC-1α–FNDC5–irisin research, and it will be stimulating to see whether this axis is part of the next generation of therapeutics for insulin-related diseases and obesity. Furthermore, PGC-1α is known to benefit tissues that do not have a primary metabolic function, such as the brain (Lin et al., 2004; Cui et al., 2006; Castillo-Quan, 2011). Thus, might FNDC5 and irisin be relevant for neurodegenerative diseases? The benefits of exercise on the brain are increasingly recognised, so it would be interesting to determine whether the muscle-derived FNDC5 can signal to the brain in an endocrine manner, perhaps improving brain function.

Acknowledgements

I would like to thank Helena M. Cochemé, Kerri J. Kinghorn and Cassandra Coburn for critical reading of this paper.

  • © 2012. Published by The Company of Biologists Ltd

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0), which permits unrestricted non-commercial use, distribution and reproduction in any medium provided that the original work is properly cited and all further distributions of the work or adaptation are subject to the same Creative Commons License terms

REFERENCES

  1. ↵
    1. Boström, P.,
    2. Wu, J.,
    3. Jedrychowski, M. P.,
    4. Korde, A.,
    5. Ye, L.,
    6. Lo, J. C.,
    7. Rasbach, K. A.,
    8. Boström, E. A.,
    9. Choi, J. H.,
    10. Long, J. Z.,
    11. et al.
    (2012). A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481, 463–468.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Castillo-Quan, J. I.
    (2011). Parkin’ control: regulation of PGC-1α through PARIS in Parkinson’s disease. Dis. Model. Mech. 4, 427–429.
    OpenUrlFREE Full Text
  3. ↵
    1. Cui, L.,
    2. Jeong, H.,
    3. Borovecki, F.,
    4. Parkhurst, C. N.,
    5. Tanese, N. and
    6. Krainc, D.
    (2006). Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127, 59–69.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Dunstan, D.
    (2011). Diabetes: exercise and T2DM-move muscles more often! Nat. Rev. Endocrinol. 7, 189–190.
    OpenUrlPubMed
  5. ↵
    1. Finck, B. N. and
    2. Kelly, D. P.
    (2006). PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J. Clin. Invest. 116, 615–622.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Handschin, C. and
    2. Spiegelman, B. M.
    (2008). The role of exercise and PGC1alpha in inflammation and chronic disease. Nature 454, 463–469.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Hiukka, A.,
    2. Maranghi, M.,
    3. Matikainen, N. and
    4. Taskinen, M. R.
    (2010). PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat. Rev. Endocrinol. 6, 454–463.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Lidell, M. E. and
    2. Enerbäck, S.
    (2010). Brown adipose tissue-a new role in humans? Nat. Rev. Endocrinol. 6, 319–325.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Lin, J.,
    2. Wu, P. H.,
    3. Tarr, P. T.,
    4. Lindenberg, K. S.,
    5. St-Pierre, J.,
    6. Zhang, C. Y.,
    7. Mootha, V. K.,
    8. Jäger, S.,
    9. Vianna, C. R.,
    10. Reznick, R. M.,
    11. et al.
    (2004). Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119, 121–135.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Narkar, V. A.,
    2. Downes, M.,
    3. Yu, R. T.,
    4. Embler, E.,
    5. Wang, Y. X.,
    6. Banayo, E.,
    7. Mihaylova, M. M.,
    8. Nelson, M. C.,
    9. Zou, Y.,
    10. Juguilon, H.,
    11. et al.
    (2008). AMPK and PPARdelta agonists are exercise mimetics. Cell 134, 405–415.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Ohno, H.,
    2. Shinoda, K.,
    3. Spiegelman, B. M. and
    4. Kajimura, S.
    (2012). PPARγ agonists Induce a White-to-Brown Fat Conversion through Stabilization of PRDM16 Protein. Cell Metab. 15, 395–404.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Ortega-Molina, A.,
    2. Efeyan, A.,
    3. Lopez-Guadamillas, E.,
    4. Muñoz-Martin, M.,
    5. Gómez-López, G.,
    6. Cañamero, M.,
    7. Mulero, F.,
    8. Pastor, J.,
    9. Martinez, S.,
    10. Romanos, E.,
    11. et al.
    (2012). Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab. 15, 382–394.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Ravussin, E. and
    2. Galgani, J. E.
    (2011). The implication of brown adipose tissue for humans. Annu. Rev. Nutr. 31, 33–47.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. van Marken Lichtenbelt, W. D.,
    2. Vanhommerig, J. W.,
    3. Smulders, N. M.,
    4. Drossaerts, J. M.,
    5. Kemerink, G. J.,
    6. Bouvy, N. D.,
    7. Schrauwen, P. and
    8. Teule, G. J.
    (2009). Cold-activated brown adipose tissue in healthy men. N. Engl. J. Med. 360, 1500–1508.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Virtanen, K. A.,
    2. Lidell, M. E.,
    3. Orava, J.,
    4. Heglind, M.,
    5. Westergren, R.,
    6. Niemi, T.,
    7. Taittonen, M.,
    8. Laine, J.,
    9. Savisto, N. J.,
    10. Enerbäck, S.,
    11. et al.
    (2009). Functional brown adipose tissue in healthy adults. N. Engl. J. Med. 360, 1518–1525.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Wenz, T.,
    2. Rossi, S. G.,
    3. Rotundo, R. L.,
    4. Spiegelman, B. M. and
    5. Moraes, C. T.
    (2009). Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc. Natl. Acad. Sci. USA 106, 20405–20410.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Zhou, Z.,
    2. Yon Toh, S.,
    3. Chen, Z.,
    4. Guo, K.,
    5. Ng, C. P.,
    6. Ponniah, S.,
    7. Lin, S. C.,
    8. Hong, W. and
    9. Li, P.
    (2003). Cidea-deficient mice have lean phenotype and are resistant to obesity. Nat. Genet. 35, 49–56.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Zingaretti, M. C.,
    2. Crosta, F.,
    3. Vitali, A.,
    4. Guerrieri, M.,
    5. Frontini, A.,
    6. Cannon, B.,
    7. Nedergaard, J. and
    8. Cinti, S.
    (2009). The presence of UCP1 demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown adipose tissue. FASEB J. 23, 3113–3120.
    OpenUrlAbstract/FREE Full Text
Previous ArticleNext Article
Back to top
Previous ArticleNext Article

This Issue

RSSRSS

 Download PDF

Email

Thank you for your interest in spreading the word on Disease Models & Mechanisms.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
From white to brown fat through the PGC-1α-dependent myokine irisin: implications for diabetes and obesity
(Your Name) has sent you a message from Disease Models & Mechanisms
(Your Name) thought you would like to see the Disease Models & Mechanisms web site.
Share
From white to brown fat through the PGC-1α-dependent myokine irisin: implications for diabetes and obesity
Jorge Iván Castillo-Quan
Disease Models & Mechanisms 2012 5: 293-295; doi: 10.1242/dmm.009894
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
From white to brown fat through the PGC-1α-dependent myokine irisin: implications for diabetes and obesity
Jorge Iván Castillo-Quan
Disease Models & Mechanisms 2012 5: 293-295; doi: 10.1242/dmm.009894

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Alerts

Please log in to add an alert for this article.

Sign in to email alerts with your email address

Article navigation

  • Top
  • Article
    • Acknowledgements
    • REFERENCES
  • Figures & tables
  • Info & metrics
  • PDF

Related articles

Cited by...

More in this TOC section

  • Modelling how initiating and transforming oncogenes cooperate to produce a leukaemic cell state
  • Finding NECA: zebrafish screen identifies key signalling pathway in β-cell regeneration
  • Lactate-starved neurons in ALS
Show more Journal Club

Similar articles

Other journals from The Company of Biologists

Development

Journal of Cell Science

Journal of Experimental Biology

Biology Open

Advertisement

Editor’s Choice – Altered expression of the Cdk5 activator-like protein, Cdk5α, causes neurodegeneration, in part by accelerating the rate of aging

By developing a comprehensive and quantitative metric for physiological age of Drosophila, Edward Giniger and colleagues show that a neurodegeneration mutant produces its effects in part by accelerating the absolute rate of aging.


First Person interviews 

Have you seen our interviews with the early-career first authors of our papers? Recently, we caught up with first authors Sarah Foriel, Henna Myllymäki and Mirja Niskanen, Wenqing Zhou, Rifdat Aoidi and Amy Irving.


Review – Metastasis in context: modeling the tumor microenvironment with cancer-on-a-chip approaches

In a new Review article, Jaap M. J. den Toonder and colleagues evaluate the recent contributions of cancer-on-a-chip models to our understanding of the tumor microenvironment and its role in the onset of metastasis. The authors also provide an outlook for future applications of this emerging technology.


DMM Conference Travel Grants

Are you an early career scientist with plans to attend a scientific meeting, conference, workshop or course relating to the areas of research covered by DMM? The next round of applications for DMM Conference Travel Grants closes on 4 May 2018. Find out more here and get your application in soon.


Why should you publish your next paper in DMM?

DMM aims to promote human health by encouraging collaboration between basic and clinical researchers, covering a diverse range of diseases, approaches and models. Our Editors are all active researchers in the field – your peers, colleagues and mentors, who know how much work has gone into every paper. Recently, we have introduced format-free submission, and we accept peer review reports from other journals, making submission as easy as possible for our authors. Send us your next great paper – publish with us and you'll be in good company.

Articles

  • Accepted manuscripts
  • Issue in progress
  • Latest complete issue
  • Issue archive
  • Archive by article type
  • Subject collections
  • Interviews
  • Alerts

About us

  • About DMM
  • Editors and Board
  • Editor biographies
  • Travelling Fellowships
  • Grants and funding
  • Workshops and Meetings
  • The Company of Biologists

For Authors

  • Submit a manuscript
  • Aims and scope
  • Presubmission enquiries
  • Article types
  • Manuscript preparation
  • Cover suggestions
  • Editorial process
  • Promoting your paper
  • Open Access
  • Biology Open transfer

Journal Info

  • Journal policies
  • Rights and permissions
  • Media policies
  • Reviewer guide
  • Alerts

Contact

  • Contact DMM
  • Advertising
  • Feedback

Twitter   YouTube   LinkedIn

© 2018   The Company of Biologists Ltd   Registered Charity 277992